Literature DB >> 19953635

Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.

Janos Sumegi1, Renae Streblow, Robert W Frayer, Paola Dal Cin, Andrew Rosenberg, Aurelia Meloni-Ehrig, Julia A Bridge.   

Abstract

The fusion oncoproteins PAX3-FOXO1 [t(2;13)(q35;q14)] and PAX7-FOXO1 [t(1;13)(p36;q14)] typify alveolar rhabdomyosarcoma (ARMS); however, 20-30% of cases lack these specific translocations. In this study, cytogenetic and/or molecular characterization to include FISH, reverse transcription polymerase chain reaction (RT-PCR), and sequencing analyses of five rhabdomyosarcomas [four ARMS and one embryonal rhabdomyosarcoma (ERMS)] with novel, recurrent t(2;2)(p23;q35) or t(2;8)(q35;q13) revealed that these noncanonical translocations fuse PAX3 to NCOA1 or NCOA2, respectively. The PAX3-NCOA1 and PAX3-NCOA2 transcripts encode chimeric proteins composed of the paired-box and homeodomain DNA-binding domains of PAX3, and the CID domain, the Q-rich region, and the activation domain 2 (AD2) domain of NCOA1 or NCOA2. To investigate the biological function of these recurrent variant translocations, the coding regions of PAX3-NCOA1 and PAX3-NCOA2 cDNA constructs were introduced into expression vectors with tetracycline-regulated expression. Both fusion proteins showed transforming activity in the soft-agar assay. Deletion of the AD2 portion of the PAX3-NCOA fusion proteins reduced the transforming activity of each chimeric protein. Similarly, but with greater impact, CID domain deletion fully abrogated the transforming activity of the chimeric protein. These studies (1) expand our knowledge of PAX3 variant translocations in RMS with identification of a novel PAX3-NCOA2 fusion, (2) show that both PAX3-NCOA1 and PAX3-NCOA2 represent recurrent RMS rearrangements, (3) confirm the transforming activity of both translocation events and demonstrate the essentiality of intact AD2 and CID domains for optimal transforming activity, and (4) provide alternative approaches (FISH and RT-PCR) for detecting PAX-NCOA fusions in nondividing cells of RMS. The latter could potentially be used as aids in diagnostically challenging cases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19953635      PMCID: PMC2808450          DOI: 10.1002/gcc.20731

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  47 in total

1.  Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity.

Authors:  C Wang; M Fu; R H Angeletti; L Siconolfi-Baez; A T Reutens; C Albanese; M P Lisanti; B S Katzenellenbogen; S Kato; T Hopp; S A Fuqua; G N Lopez; P J Kushner; R G Pestell
Journal:  J Biol Chem       Date:  2001-03-09       Impact factor: 5.157

2.  Translocation (2;8)(q35;q13): a recurrent abnormality in congenital embryonal rhabdomyosarcoma.

Authors:  Aurelia Meloni-Ehrig; Bridget Smith; Joanna Zgoda; Jay Greenberg; Eva Perdahl-Wallace; Syed Zaman; Philip Mowrey
Journal:  Cancer Genet Cytogenet       Date:  2009-05

3.  Regulation of the homeodomain CCAAT displacement/cut protein function by histone acetyltransferases p300/CREB-binding protein (CBP)-associated factor and CBP.

Authors:  S Li; B Aufiero; R L Schiltz; M J Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

4.  Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities.

Authors:  S S Koh; D Chen; Y H Lee; M R Stallcup
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

5.  Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study.

Authors:  J A Bridge; J Liu; V Weibolt; K S Baker; D Perry; R Kruger; S Qualman; F Barr; P Sorensen; T Triche; R Suijkerbuijk
Journal:  Genes Chromosomes Cancer       Date:  2000-04       Impact factor: 5.006

6.  Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group.

Authors:  Elai Davicioni; Michael J Anderson; Friedrich Graf Finckenstein; James C Lynch; Stephen J Qualman; Hiroyuki Shimada; Deborah E Schofield; Jonathan D Buckley; William H Meyer; Poul H B Sorensen; Timothy J Triche
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

7.  ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations.

Authors:  Sabine Strehl; Karin Nebral; Margit König; Jochen Harbott; Herbert Strobl; Richard Ratei; Stephanie Struski; Bella Bielorai; Michel Lessard; Martin Zimmermann; Oskar A Haas; Shai Izraeli
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

8.  NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia.

Authors:  S Esteyries; C Perot; J Adelaide; M Imbert; A Lagarde; C Pautas; S Olschwang; D Birnbaum; M Chaffanet; M-J Mozziconacci
Journal:  Leukemia       Date:  2007-09-06       Impact factor: 11.528

9.  MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish.

Authors:  Julia Zhuravleva; Jérôme Paggetti; Laurent Martin; Arlette Hammann; Eric Solary; Jean-Noël Bastie; Laurent Delva
Journal:  Br J Haematol       Date:  2008-08-20       Impact factor: 6.998

10.  CREB-binding protein (CBP)/p300 and RNA polymerase II colocalize in transcriptionally active domains in the nucleus.

Authors:  A von Mikecz; S Zhang; M Montminy; E M Tan; P Hemmerich
Journal:  J Cell Biol       Date:  2000-07-10       Impact factor: 10.539

View more
  58 in total

1.  Novel PAX3-NCOA1 Fusions in Biphenotypic Sinonasal Sarcoma With Focal Rhabdomyoblastic Differentiation.

Authors:  Shih-Chiang Huang; Ronald A Ghossein; Justin A Bishop; Lei Zhang; Tse-Ching Chen; Hsuan-Ying Huang; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-01       Impact factor: 6.394

2.  Clinical utility gene card for: Alveolar rhabdomyosarcoma.

Authors:  Zhongxin Yu; Anna Kelsey; Rita Alaggio; David Parham
Journal:  Eur J Hum Genet       Date:  2011-08-10       Impact factor: 4.246

Review 3.  Histiocytic neoplasms in the era of personalized genomic medicine.

Authors:  Benjamin H Durham; Eli L Diamond; Omar Abdel-Wahab
Journal:  Curr Opin Hematol       Date:  2016-07       Impact factor: 3.284

Review 4.  Biphenotypic sinonasal sarcoma: demographics, clinicopathological characteristics, molecular features, and prognosis of a recently described entity.

Authors:  Simon Andreasen; Justin A Bishop; Henrik Hellquist; Jennifer Hunt; Katalin Kiss; Alessandra Rinaldo; Alena Skálová; Stefan M Willems; Michelle Williams; Alfio Ferlito
Journal:  Virchows Arch       Date:  2018-08-14       Impact factor: 4.064

Review 5.  New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: Nasal cavity, paranasal sinuses and skull base.

Authors:  Lester D R Thompson; Alessandro Franchi
Journal:  Virchows Arch       Date:  2017-04-25       Impact factor: 4.064

Review 6.  The current landscape of rhabdomyosarcomas: an update.

Authors:  Julia Leiner; François Le Loarer
Journal:  Virchows Arch       Date:  2019-11-06       Impact factor: 4.064

7.  Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Distinct Entity Characterized by Recurrent NCOA2/3 Gene Fusions.

Authors:  Brendan C Dickson; Timothy J Childs; Terrence J Colgan; Yun-Shao Sung; David Swanson; Lei Zhang; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2019-02       Impact factor: 6.394

8.  Updates on the cytogenetics and molecular cytogenetics of benign and intermediate soft tissue tumors.

Authors:  Jun Nishio
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

9.  PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.

Authors:  Stephen X Skapek; James Anderson; Frederic G Barr; Julia A Bridge; Julie M Gastier-Foster; David M Parham; Erin R Rudzinski; Timothy Triche; Douglas S Hawkins
Journal:  Pediatr Blood Cancer       Date:  2013-03-22       Impact factor: 3.167

10.  Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing.

Authors:  Matthew R Avenarius; Cecelia R Miller; Michael A Arnold; Selene Koo; Ryan Roberts; Martin Hobby; Thomas Grossman; Yvonne Moyer; Richard K Wilson; Elaine R Mardis; Julie M Gastier-Foster; Ruthann B Pfau
Journal:  J Mol Diagn       Date:  2020-08-01       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.